Aplidine

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Aplidine 具有针对 SARS-CoV-2 的抗病毒活性（IC90 = 0.88 nM）。 Aplidine 是一种有效的抗癌剂，通过靶向真核翻译延伸因子 1 Alpha 2（EEF1A2，Kd = 80 nM）。

Aplidine possesses antiviral activity against SARS-CoV-2(IC90 = 0.88 nM). Aplidine is a potent anti-cancer agent by targeting eukaryotic translation elongation factor 1 Alpha 2(EEF1A2, Kd = 80?nM).(In Vitro):In hACE2-293T cells, Aplidine exhibits anti–SARS-CoV-2 activity with an IC90 of 0.88 nM. In an established model of human pneumocyte-like cells, Aplidine inhibits SARS-CoV-2 replication with an IC90 of 3.14 nM and a selectivity index of 40.4. Aplidine (20 nM; 1 h) induces a dose-dependent decrease in VEGF secretion in MOLT-4 cells. Aplidine (20 nM; 1 h) does not result in significant inhibition of VEGF-R1 mRNA in normal endothelial cells, which do express VEGFR-1 but do not secrete VEGF.(In Vivo):In BALB/c mice expressing human ACE2, Aplidine significantly reduced SARS-CoV-2 infection. 0.3 mg/kg Aplidine group results in a reduction of nearly 2 log units in SARS-CoV-2 viral titers in the lungs, and the 1 mg/kg group leads to a reduction of 1.5 log units.

——

Animal Model:BALB/c mice Dosage:0.3 mg/kg; 1 mg/kg Administration:1 day QD at 1 mg/kg; 3days QD at 0.3 mg/kg Result:Showed in vivo antiviral efficacy in mouse models of SARS-CoV-2 infection.

Plitidepsin

Others

Other Targets

EP1

——

——

137219-37-5

1110.34

C57H87N7O15

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (90.06 mM)

CC[C@@H]([C@@H]1[C@@H](O)CC(O[C@@H](C(C)C)C([C@H](C)C(N[C@@H](CC(C)C)C(N2CCC[C@H]2C(N(C)[C@@H](CC3=CC=C(OC)C=C3)C(O[C@H](C)[C@H](NC([C@H](N(C([C@@H]4CCCN4C(C(C)=O)=O)=O)C)CC(C)C)=O)C(N1)=O)=O)=O)=O)=O)=O)=O)C

——

(-20℃)

With Ice Pack

≥ 2 years